TABLE 3.

Summary of the intervention studies on the application of CMV-CMI assays in SOT recipients.

Study author	Number of patients	Type of organ transplant	CMV serostatus	Cell-mediated immune assay	Intervention	Main results
[106]	118	Lung	R+ and D+/R−	QTF-CMV	Test at 5, 8 and 11 months, stop prophylaxis if test positive	Lower CMV replication in the allograft and longer duration of antiviral prophylaxis in the intervention group
[107]	150	Kidney	R+ on ATG	QTF-CMV	Test at 30, 45, 60, 90 days, stop prophylaxis if test positive	Similar incidence of CMV replication/disease, shorter duration of antiviral, lower incidence of neutropenia in the intervention group
[108]	185	Kidney (164) and liver (21)	R+ on ATG and D+/R−	T-Track-CMV	Test at 30, 60, 90 days (R+ and D+/R−), 120, 150, 180 (D+/R−), stop prophylaxis if test positive	Similar incidence of CMV replication/disease, shorter duration of antiviral in the intervention group
[109]	27	All SOT	R+ and D+/R−	QTF-CMV	Test at the end of therapy for CMV replication, add secondary prophylaxis in case of negative result	Lower incidence of CMV relapse in patients with a positive test
[110]	160	Kidney	R+	T-SPOT.CMV	Stratify patients at transplant in low vs. high-risk according to test result. Then randomize to preemptive vs. prophylaxis	Higher incidence of CMV replication in high-risk group. Better performance of antiviral prophylaxis strategy in both groups

ATG, anti-thymocyte globulin; CMV, cytomegalovirus; D, donor; QTF-CMV, QuantiFERON-CMV assay; R, recipient.